Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Fly 27% But Investors Aren't Buying For Growth

Simply Wall StDec 3 05:14 ET

RBC Capital Remains a Hold on Apellis Pharmaceuticals (APLS)

TipRanksNov 27 20:48 ET · Ratings

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

Apellis PharmaceuticalsNov 27 00:00 ET

A Glimpse Into The Expert Outlook On Apellis Pharmaceuticals Through 20 Analysts

BenzingaNov 21 07:00 ET

Apellis Pharmaceuticals Initiated at Equal-Weight by Morgan Stanley

Dow JonesNov 21 06:33 ET · Ratings

Morgan Stanley Initiates Apellis Pharmaceuticals(APLS.US) With Hold Rating, Announces Target Price $31

Moomoo NewsNov 21 05:32 ET · Ratings